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Alexis Poole1, Adam Deane1,2, Matthew Summers1,2, Janice Fletcher3 and Marianne Chapman1,2*Abstract
Introduction: In this study, we aimed to evaluate whether fasting plasma citrulline concentration predicts
subsequent glucose absorption in critically ill patients.
Methods: In a prospective observational study involving 15 healthy and 20 critically ill subjects, fasting plasma
citrulline concentrations were assayed in blood samples immediately prior to the administration of a liquid test
meal (1 kcal/ml; containing 3 g of 3-O-methylglucose (3-OMG)) that was infused directly into the small intestine.
Serum 3-OMG concentrations were measured over the following 4 hours, with the area under the 3-OMG concentration
curve (AUC) calculated as an index of glucose absorption.
Results: The groups were well matched in terms of age, sex and body mass index (BMI) (healthy subjects versus
patients, mean (range) values: age, 47 (18 to 88) versus 49 (21 to 77) years; sex ratio, 60% versus 80% male; BMI, 25.2
(18.8 to 30.0) versus 25.5 (19.4 to 32.2) kg/m2). Compared to the healthy subjects, patients who were critically ill had
reduced fasting citrulline concentration (26.5 (13.9 to 43.0) versus 15.2 (5.7 to 28.6) μmol/L; P < 0.01) and glucose
absorption (3-OMG AUC, 79.7 (28.6 to 117.8) versus 61.0 (4.5 to 97.1) mmol/L/240 min; P = 0.05). There was no
relationship between fasting citrulline concentration and subsequent glucose absorption (r = 0.28; P = 0.12).
Conclusions: Whereas both plasma citrulline concentrations and glucose absorption were reduced in critical illness,
fasting plasma citrulline concentrations were not predictive of subsequent glucose absorption. These data suggest that
fasting citrulline concentration does not appear to be a marker of small intestinal absorptive function in patients who
are critically ill.Introduction
Nutritional therapy is an integral component of the
management of patients admitted to the intensive care
unit (ICU) who are critically ill, and the enteral route
is preferred to intravenous feeding [1,2]. However,
it has recently been demonstrated that enteral nutrient
absorption is impaired in a variable, unpredictable and
unquantifiable way [3-6]. As adequate energy delivery is
important for optimal clinical outcomes, it would be
beneficial to be able to identify, in the clinical setting,* Correspondence: marianne.chapman@health.sa.gov.au
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and be able to quantify this.
Plasma concentration of the amino acid citrulline,
which is synthesized mainly in the small intestine, is re-
duced in specific disease states, including Crohn’s dis-
ease, coeliac disease and short bowel syndrome, and this
probably reflects reduced functional enterocyte mass
[7-14]. However, conflicting results have been reported
by researchers who have looked at whether plasma cit-
rulline concentrations predict small intestinal absorptive
function in patients with short bowel syndrome [7,9,15].
Plasma citrulline concentrations have been measured in
patients who are critically ill, with low concentrations
documented [13,14,16], suggesting that critical illness
may also be associated with a reduction in functional en-
terocyte mass [14]. Piton et al. reported that very low
citrulline concentrations were associated with increasedhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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have resulted from gastrointestinal damage [13,14,17]. Al-
though it has been suggested that citrulline concentration
may be a marker of small intestinal absorptive function,
the relationship between macronutrient absorption and
citrulline concentration has not been evaluated in patients
who are critically ill. If citrulline concentration were able
to accurately identify and quantify impaired small intes-
tinal absorption in patients who are critically ill, such a
marker would provide valuable clinical information that
would aid in optimising nutritional support. Therefore,
the aim of this study was to evaluate the relationship be-
tween fasting plasma citrulline levels and small intestinal
glucose absorption in critically ill patients and compare
the results to healthy subjects.
Material and methods
Following approval by the Human Research Ethics Com-
mittee of the Royal Adelaide Hospital, a prospective ob-
servational study involving critically ill patients and
healthy subjects was undertaken according to guidelines
on research conducted on unconscious patients as out-
lined by the National Health and Medical Research
Council of Australia. Informed written consent for each
patient was obtained from the next of kin and from the
healthy subjects themselves.
Participants
Mechanically ventilated (≥72 hours) adult (≥18 years)
patients were recruited from the Royal Adelaide Hospital
ICU, a 24-bed mixed medical-surgical ICU at a large
university-affiliated metropolitan teaching hospital in
South Australia. Patients were receiving or were suitable
to receive postpyloric enteral feeding. Exclusion criteria
included pregnancy, history of diabetes mellitus, previ-
ous abdominal surgery, receiving erythromycin at an
antimicrobial dose and/or receiving parenteral nutrition.
Healthy adult subjects were recruited from advertise-
ments and from records kept by the Intensive Care Re-
search Unit of persons potentially prepared to volunteer
for research studies. Subjects who had previously under-
gone insertion of a nasogastric tube were preferred, as
stress and anxiety relating to tube insertion may affect
gastrointestinal function, which would be less likely in
individuals with such experience [18]. Healthy subjects
were excluded if they were pregnant or breastfeeding,
had undergone previous abdominal surgery, had current
or previous gastrointestinal disease or were taking medi-
cations known to affect gastrointestinal motility. Older,
male healthy subjects with a higher BMI were specific-
ally sought in an attempt to match the critically ill popu-
lation with respect to sex, age and BMI, as it is known
that small intestinal function may vary with these pa-
rameters [19-21].Study protocol
Critically ill subjects were fasted for a minimum of
6 hours prior to study commencement. Those prescribed
prokinetic agents had doses held prior to and during the
study. A postpyloric feeding tube was inserted using an
electromagnetic guidance technique (CORTRAK 2 EAS
enteral access system; CORPAK MedSystems, Buffalo
Grove, IL, USA), which uses a proprietary feeding catheter
that contains a removable stylet with an electromagnetic
transmitter, receiver unit and placement monitor [22]. Ac-
curate placement was confirmed based on an abdominal
radiograph. An arterial line, part of the routine care of
ICU patients, was used for blood-sampling purposes.
The healthy subjects attended the ICU research centre
at the Royal Adelaide Hospital at 8:00 AM following an
overnight fast. After administration of a local anaesthetic
throat spray (Co-Phenylcaine Forte Spray; ENT Tech-
nologies, Hawthorn East, VIC, Australia), a silicone rub-
ber catheter (Mui Scientific, Mississauga, ON, Canada)
that had seven side holes at 1.5-cm intervals and a duo-
denal feeding port was inserted into the stomach with
the aid of tip weights. The healthy subject then assumed
the right lateral position to aid migration of the catheter
into the duodenum. Accurate placement was confirmed
based on antroduodenal transmucosal potential difference.
The study commenced once all side holes were confirmed
to be in the duodenum [23]. A 20-gauge intravenous can-
nula was inserted into an antecubital vein to allow blood
sampling.
Following confirmation of correct tube placement, all par-
ticipants received the test ‘meal’. This consisted of 100 ml
of liquid nutrient (1 kcal/ml Ensure; Abbott Australasia,
Botany, NSW, Australia) mixed with 3 g of 3-O-methylglu-
cose (3-OMG) (Sigma-Aldrich, Castle Hill, NSW, Australia).
3-OMG is a synthetic sugar that is absorbed by the same
mechanism as glucose but is metabolically inert, meaning
that plasma levels of 3-OMG reflect glucose absorption
[5]. This meal was infused via the postpyloric tube directly
into the small intestine over a period of 6 minutes, using a
syringe driver (Alaris GH plus Mk3; CareFusion, Rolle,
Switzerland) to provide consistent flow.
Outcome measures
We recorded descriptive data, including demographic
variables, and, for patients, admission diagnosis, disease
severity scores (Acute Physiology and Chronic Health
Evaluation II score on the day of the study), serum cre-
atinine and 90-day mortality.
Blood samples were drawn at baseline (prior to deliv-
ery of the test meal) and at 5, 15, 30, 45, 60, 90, 120,
150, 180, 210 and 240 minutes following the infusion of
the test meal. Plasma samples were immediately placed
in a cooled storage container and then centrifuged at
3,200 rpm for 15 minutes at 4°C (Universal 320R centrifuge;









Age (years)a 49 (21 to 77) 47 (18 to 88) 0.80
Sexb 0.20
Male 16 (80%) 9 (60%)
Female 4 (20%) 6 (40%)
Body mass indexb
(kg/m2)
25.5 (19.4 to 32.2) 25.2 (18.8 to 30.0) 0.84
Admission diagnosisc





Cardiac surgery 1 (5%)
Pancreatitis 1 (5%)
Sepsis 1 (5%)
APACHE II scored 18 (4 to 27) N/A N/A
Serum creatinineb
(μmol//L)
91.2 (31 to 357) N/A N/A
90 day mortalityc 2 (10%) N/A N/A
aAPACHE, Acute Physiology and Chronic Health Evaluation; ARDS, Acute
respiratory distress syndrome; N/A, Not applicable. bMean (range). cNumber
(percentage). dMedian (range).
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anted and placed in 5-ml collection tubes and stored in a
monitored −80°C specimen freezer (MDF-U74V; Sanyo
Electric Co, Osaka, Japan) until analysis was performed.
Serum samples were kept at room temperature for 30 to
60 minutes to allow clot formation to occur, then centri-
fuged as above, decanted into 5-ml aliquots and placed
into a monitored −80°C specimen freezer. Serum 3-OMG
concentrations were measured using liquid chromatog-
raphy/mass spectroscopy. Citrulline concentrations were
determined by stable isotope dilution tandem mass
spectrometry (coefficient of variation, <10%). (API 4000;
AB SCIEX, Framingham, MA, USA) at the SA Path-
ology laboratory (Women’s and Children’s Hospital,
North Adelaide, SA, Australia) [24].
Statistical analysis
The area under the 3-OMG concentration curve (AUC)
was used to quantify glucose absorption [3] and was cal-
culated using the trapezium rule [25]. Independent sam-
ples t-tests were used to compare data between the
critically ill patients and healthy subjects. Critically ill
patients and healthy subjects were considered separately
and as a single cohort when analysing for potential rela-
tionships between plasma citrulline concentrations and
glucose absorption (3-OMG AUC). These relationships
were analysed using Pearson’s correlation coefficient to
examine a linear association between two normally
distributed variables. The two time points selected to
measure 3-OMG AUC were 60 minutes postmeal,
reflecting early absorption, and 240 minutes postmeal,
reflecting overall absorption at the completion of data
collection. Analyses were performed using IBM SPSS
Statistics version 20.0 software (SPSS, Chicago, IL,
USA), and statistical significance was defined as P ≤ 0.05.
Results
Twenty-one critically ill patients and seventeen healthy
subjects were recruited into the study. One patient and
two healthy subjects had incomplete blood sampling due
to line blockage or removal. Their data were excluded,
leaving 20 critically ill patients and 15 healthy subjects
included in the analyses. The study was well tolerated,
with no adverse events. Descriptive data, including
demographic variables and illness severity, are presented
in Table 1.
Fasting plasma citrulline concentration was signifi-
cantly reduced in the critically ill patients compared to
the healthy subjects (P < 0.01) (Figure 1). Similarly, glu-
cose absorption (3-OMG AUC at 240 minutes postmeal)
was reduced in the critically ill patients compared to the
healthy subjects (P = 0.050) (Figure 2A,B).
No association was found between fasting citrulline con-
centration and subsequent glucose absorption (3-OMGAUC at 60 and 240 minutes postmeal) for the group as a
whole (at 60 minutes: r = 0.21, P = 0.25; at 240 minutes:
r = 0.28, P = 0.12). Similarly, no association was found
when the critically ill patients and healthy subjects were
considered on their own at either 60 minutes (critically
ill patients: r = −0.008, P = 0.97; healthy subjects: r = 0.24,
P = 0.43) or 240 minutes (critically ill patients: r = 0.16,
P = 0.51; healthy subjects: r = −0.04, P = 0.90) postmeal.
Figure 3 shows a scatterplot of the results for the entire
sample at 240 minutes postmeal.
Discussion
The aim of this study was to examine the relationship
between fasting plasma citrulline concentration and
small intestinal glucose absorption in critically ill pa-
tients and healthy subjects. In so doing, we sought to as-
sess whether citrulline concentration could be used as a
biomarker to identify and quantify this aspect of small
intestinal function in patients who are critically ill. To
our knowledge, this is the first study to examine this re-
lationship. Although citrulline concentrations were re-
duced and glucose absorption was impaired in the
critically ill patients, there was no relationship between
fasting citrulline concentration and subsequent glucose
absorption. These results suggest that fasting plasma
Figure 1 Fasting plasma citrulline concentrations in healthy subjects and critically ill patients.
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sorption in critical illness or in health.
The findings related to reduced citrulline concentra-
tion and impaired glucose absorption confirm previous
findings. Reference values determined in other laborator-
ies for citrulline concentrations are 24 to 50 μmol/L in
healthy subjects and 10 to 29 μmol/L in critically ill pa-
tients [26], which are consistent with the values reported
in our present study [27-36]. Reduced citrulline concen-
tration has been associated with illness severity and with
poor outcome [16,17,37]. The data for glucose absorp-
tion using 3-OMG concentration are similar to those re-
ported by our group previously [3,4].
Despite both fasting plasma citrulline concentration
and overall glucose absorption being reduced in our
sample of critically ill patients, we did not find an associ-
ation between the two. There are a number of possible
reasons for this. Although the mechanisms underlying
impaired glucose absorption in critical illness are uncer-
tain, they are likely to be multifaceted, with factors in-
cluding the rate of gastric emptying, intestinal transit
time, duodenal and/or jejunal flow events [3,6], the in-
tegrity of surface villi and the presence and function of
sodium-glucose active transport molecules on intestinal
enterocytes [4,38]. In the setting of these multifactorial
influences, our results suggest that citrulline concentration
may not be sufficiently sensitive to indicate carbohydrate
malabsorption or reflect the absorptive capacity of the
small intestine. Furthermore, in patients who are critically
ill, in whom multisystem dysfunction is commonplace, it
is possible that citrulline concentration does not justreflect reduced synthesis by the small intestinal entero-
cytes [13], but may also be simultaneously increased by
renal dysfunction [39], because most citrulline degradation
occurs in the proximal tubules of the kidney. Hence, the
degree of reduction in citrulline concentration may be
curtailed in the presence of renal dysfunction, which in
turn could contribute to a lack of a relationship between
citrulline concentration and small intestinal glucose ab-
sorption. The mean creatinine concentration in the pa-
tients in this study was in the normal range, so this may
not have been an important factor in most of the patients
studied; nevertheless, it is a consideration, as four patients
had abnormal renal function as defined by a creatinine
level >100 μmol/L. Furthermore, the importance of renal
failure as an influence on citrulline concentration in crit-
ical illness has been questioned [40].
Although it is frequently stated that citrulline concen-
tration can be used to assess enterocyte function, few
studies have quantified the relationship between citrul-
line and intestinal absorption, and those that have been
performed have produced conflicting results. Our results
are at odds with those reported by Papadia et al. [11].
They examined the relationship between citrulline con-
centration and xylose absorption using urine sampling
in 55 patients with Crohn’s disease and short bowel syn-
drome. They found a strong correlation between bowel
length and citrulline concentration and also between xy-
lose absorption and citrulline concentration. There are a
number of possible explanations for these conflicting re-
sults. First, it is possible, or indeed likely, that citrulline
concentration reflects absorptive function in short bowel
Figure 2 Comparison of glucose absorption in healthy and critically ill patients. (A) Glucose absorption assessed using 3-O-methylglucose
(3-OMG) concentration against time and the area under the 3-OMG curve (3-OMG AUC) in critically ill patients and healthy subjects. (B) Total
glucose absorption in critically ill and healthy subjects using 3-OMG concentration.
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bowel syndrome will inevitably have impaired nutrient
absorption directly related to the remaining length of
short bowel, which will also reflect intestinal synthetic
function. Patients who are critically ill may have reduced
small intestinal synthetic function, but, as suggested
above, their impaired absorption may have mechanisms
other than reduced enterocyte mass. Another factor that
may account for the differing results is the use of differ-
ent techniques for the measurement of nutrient absorp-
tion. Xylose is a pentose sugar, whereas glucose is a
hexose. The absorptive mechanism differs between the
two agents, and there is redundancy in the absorption of
glucose, making it much less likely to be affected bysmall intestinal pathology. Nevertheless, glucose absorp-
tion has repeatedly been shown to be impaired in pa-
tients who are critically ill [3,4], and the analysis of
plasma concentration of 3-OMG is likely to be more
clinically relevant, as glucose is a source of calories in
enteral nutrition formulae. It is conceivable that if an-
other probe is used, a relationship between citrulline
and nutrient absorption may be demonstrated in pa-
tients who are critically ill. Citrulline concentration has
been shown to have some correlation with fat (r = 0.53)
and nitrogen (r = 0.47) absorption in short bowel syn-
drome [7]. Our results are consistent with those of a
study of 24 patients with short bowel syndrome in
whom macronutrient absorption, measured using acid
Figure 3 Scatterplot of glucose absorption and fasting plasma citrulline concentration for the entire cohort. Data are represented as area
under the curve for serum 3-O-methylglucose concentration (3-OMG AUC) at 240 minutes postmeal.
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citrulline concentration [15]. It appears that, although
citrulline concentration may reflect enterocyte mass, it
may not reflect enterocyte function in critical illness.
Hence, unfortunately, citrulline cannot be used as an in-
dicator of glucose absorption in critical illness.
A limitation of our study is that, although the sample
size in the current study was sufficient to be able to
demonstrate significant differences between critically ill
patients and healthy subjects with regard to citrulline
concentration and glucose absorption, it may have been
underpowered to detect a relationship between citrulline
concentration and glucose absorption. Although the diet
of participants was not controlled prior to recruitment,
the fasting period before data collection should have
been sufficient to prevent any residual dietary effects on
the outcomes, particularly because the only important
source of citrulline is watermelon. A previous study
showed that even administration of a high ‘dose’ of
watermelon did not increase plasma citrulline concen-
tration [41]. It is also possible that using a test sugar
other than 3-OMG or another macronutrient and meas-
urement of citrulline concentration on more than one
occasion may have generated different results.
Conclusions
This study confirms that fasting plasma citrulline con-
centration and glucose absorption are reduced in the
critically ill when compared to healthy subjects. However,fasting plasma citrulline concentration does not appear to
be a marker of subsequent glucose malabsorption. Ac-
cordingly, plasma citrulline concentration does not appear
to be a robust measure of this aspect of small intestinal
function in patients who are critically ill, but this may war-
rant further investigation with other macronutrients.
Key messages
 Fasting plasma citrulline concentrations are reduced
in critically ill patients compared to healthy subjects.
 Glucose absorption is reduced in critically ill
patients compared to healthy subjects.
 Fasting plasma citrulline concentration does not
appear to be a marker of glucose malabsorption.
 Although it has been suggested that citrulline is a
biomarker of intestinal function, it does not appear
to be a biomarker of glucose absorptive function.
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